Pasar al contenido principal

Resultados relacionados

Resultados totales (Incluyendo duplicados): 3
Encontrada(s) 1 página(s)

Zaguán. Repositorio Digital de la Universidad de Zaragoza
Publicación Artículo científico (JournalArticle)

Concomitant anti-CGRP and immunomodulatory treatments in patients with migraine: towards integrated management strategies

  • García-Castillo, María Clara
  • Sierra-Mencía, Álvaro
  • Caronna, Edoardo
  • Toledo-Alfocea, Daniel
  • Jaimes, Alex
  • Urtiaga, Saray
  • Casas-Limón, Javier
  • Muñoz-Vendrell, Albert
  • Santos Lasaosa, Sonia
  • García Martín, Valvanuz
  • Martín Ávila, Guillermo
  • Polanco, Marcos
  • Villar-Martínez, Maria Dolores
  • Trevino-Peinado, Cristina
  • Rubio-Flores, Laura
  • Sánchez-Soblechero, Antonio
  • Portocarrero Sánchez, Leonardo
  • Luque-Buzo, Elisa
  • Lozano-Ros, Alberto
  • Gago-Veiga, Ana Beatriz
  • Díaz-De-Terán, Javier
  • Recio García, Andrea
  • Canales Rodríguez, Javiera
  • Gómez García, Andrea
  • González Salaices, Marta
  • Campoy, Sergio
  • Mínguez-Olaondo, Ane
  • Maniataki, Stefania
  • González-Quintanilla, Vicente
  • Porta-Etessam, Jesús
  • Cuadrado, María-Luz
  • Guerrero Peral, Ángel Luis
  • Pozo-Rosich, Patricia
  • Rodríguez-Vico, Jaime
  • Huerta-Villanueva, Mariano
  • Pascual, Julio
  • Goadsby, Peter J.
  • Gonzalez-Martinez, Alicia
Preclinical evidence supports the immunoregulatory role of calcitonin gene-related peptide (CGRP) in migraine pathophysiology. The increasing use of anti-CGRP therapies in patients with migraine and other comorbidities raises the question whether the potential use of anti-CGRP monoclonal antibodies (CGRP-mAbs) therapies in combination with other immunological therapies is effective and safe. Methods. This multicenter study included patients with migraine receiving CGRP-mAbs combined with immunosuppressive and immunomodulatory treatments. Clinical and demographic data, treatment history, laboratory markers and treatment-emergent adverse events (TEAEs) were analyzed. Effectiveness outcomes included the change in monthly migraine days (MMD) and monthly headache days (MHD) at 3, 6, 9 and 12 months, alongside the > 50% response rate. Moreover, autoimmune disease progression was also evaluated. We explored differences between patients with and without autoimmune disease activation. Results.Among 89 patients, there were 80 (90%) females with a mean age of 50 years (SD: 11), who had a high prevalence of psychiatric comorbidities (anxiety 44%, depression 49%) and medication overuse (68%). Patients receiving immunological treatments experienced significant reductions in MMD and MHD, with MMD decreasing from 16 (SD: 7) at baseline to 9 (SD: 8) at 6 months, and MHD dropping from 23 (SD: 8) to 17 (SD: 11). A 50% response in MMD was achieved by 46% at 6 months. TEAEs were reported in 28%, most commonly constipation (16%) and dizziness (9%). Conclusions. CGRP-mAbs therapies combined with immunological treatments appear effective and safe in patients with autoimmune diseases. Larger prospective studies are necessary to confirm these findings and optimize management strategies.
Zaguán. Repositorio Digital de la Universidad de Zaragoza
Publicación Artículo científico (JournalArticle)

Evaluation of the effectiveness and safety of anti-CGRPmonoclonal antibodies in patients with migraine andautoimmune diseases: IMMUNO-CGRP study

  • García-Castillo, María Clara
  • Sierra-Mencía, Álvaro
  • Caronna, Edoardo
  • Toledo-Alfocea, Daniel
  • Jaimes, Alex
  • Urtiaga, Sarai
  • Casas-Limón, Javier
  • Muñoz-Vendrell, Albert
  • Santos-Lasaosa, Sonia
  • García Martín, Valvanuz
  • Martín Ávila, Guillermo
  • Polanco, Marcos
  • Villar-Martínez, Maria Dolores
  • Trevino-Peinado, Cristina
  • Rubio-Flores, Laura
  • Sánchez-Soblechero, Antonio
  • Portocarrero Sánchez, Leonardo
  • Luque-Buzo, Elisa
  • Lozano-Ros, Alberto
  • Gago-Veiga, Ana Beatriz
  • Díaz-De-Terán, Javier
  • Recio García, Andrea
  • Canales Rodríguez, Javiera
  • Gómez García, Andrea
  • González Salaices, Marta
  • Campoy, Sergio
  • Mínguez-Olaondo, Ane
  • Maniataki, Stefania
  • González-Quintanilla, Vicente
  • Porta-Etessam, Jesús
  • Cuadrado, María-Luz
  • Guerrero Peral, Ángel Luis
  • Pozo-Rosich, Patricia
  • Rodríguez-Vico, Jaime
  • Huerta-Villanueva, Mariano
  • Pascual, Julio
  • Goadsby, Peter J.
  • Gonzalez-Martinez, Alicia
Objective: This study aimed to evaluate demographic characteristics, treatment effectiveness, and safety outcomes in patients with migraine undergoing anti‐calcitonin gene‐related peptide (CGRP) treatments regarding the presence of autoimmune diseases. Background: CGRP has an important role in migraine pathophysiology through neuronal modulation in the trigeminovascular nociceptive system and activation of neuro‐inflammatory cascades. We hypothesized that autoimmune diseases may influence treatment response and safety profiles in patients with migraine treated with anti‐CGRP treatments. Methods: This was a retrospective multicenter, age‐ and sex‐matched cohort study in headache units/headache clinics in Spain and United Kingdom between May 2024 and May 2025 including patients treated with CGRP monoclonal antibodies from prospectively collected cohorts. Patients were assessed for demographics, migraine‐related characteristics, treatment effectiveness (monthly migraine days [MMD] and/or monthly headache days [MHD]), and safety outcomes. The main outcome was the effectiveness measured by ≥50% response rate in MMD between the two groups. Secondary outcomes included other effectiveness measurements regarding the number of MMD and MHD and treatment emerging adverse events. Results: A total of 388 patients with migraine under anti‐CGRP treatments (194 with autoimmune diseases and 194 age‐ and sex‐matched controls without autoimmune diseases) were included. The proportion of patients achieving a ≥50% response rate in MMD was higher in patients without autoimmune diseases at 6 (69% vs. 53%; p = 0.006) and 9 months (74% vs. 52%; p = 0.006). Treatment emerging adverse events were comparable between the two groups (35% vs. 38%; p = 0.575). Patients with autoimmune disease had a significantly lower likelihood of achieving a ≥50% response in MMD compared with those without autoimmune disease (adjusted odds ratio, 0.61; 95% confidence interval, 0.44–0.85; p = 0.006), independent of comorbid depression and medication overuse. Conclusions: Our study shows that anti‐CGRP treatments are effective and safe for patients with migraine regardless the presence of autoimmune diseases, although an increased treatment response in patient without autoimmune disorders compared to patients with autoimmune disorders was observed. These findings highlight the need for early intervention, tailored strategies, and vigilant monitoring in patients with migraine and autoimmune disorders. Further research should explore immunomodulatory approaches to enhance outcomes.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

RE-START, Exploring the effectiveness of anti-calcitonin gene-related peptide resumption after discontinuation in migraine

  • Romero del Rincón, Celia|||0000-0002-0339-6616
  • Gonzalez-Martinez, Alicia|||0000-0002-1228-1503
  • Quintas, Sonia|||0000-0003-0622-8228
  • Garcia Azorin, David|||0000-0002-3132-1064
  • Fernández-Lázaro, Iris|||0009-0004-2544-5206
  • Guerrero Peral, Ángel Luis|||0000-0001-7493-6002
  • González Osorio, Yésica|||0000-0003-1461-9798
  • Santos Lasaosa, Sonia|||0000-0002-4141-7705
  • González Oria, Carmen
  • Sánchez Rodríguez, Norberto
  • Iglesias Díez, Fernando
  • Echavarría Íñiguez, Ana|||0000-0001-7038-2911
  • Gil Luque, Sendoa
  • Huerta, Mariano|||0000-0003-0181-5335
  • Campoy Diaz, Sergio|||0000-0002-8135-4139
  • Muñoz-Vendrell, Albert|||0000-0001-8221-865X
  • Lozano Ros, Alberto|||0000-0002-5186-8657
  • Sánchez-Soblechero, Antonio|||0000-0002-7098-8494
  • Velasco Juanes, Fernando
  • Kortazar-Zubizarreta, Izaro|||0000-0002-8107-660X
  • Echeverría, Amaya|||0000-0001-9225-5323
  • Rodríguez-Vico, Jaime|||0000-0001-9360-5444
  • Jaimes Sánchez, Alex
  • Gómez García, Andrea
  • Morollón Sánchez-Mateos, Noemí|||0000-0003-4256-4210
  • Belvís, Roberto|||0000-0002-2137-180X
  • Navarro Pérez, María Pilar|||0000-0001-6370-218X
  • García-Moncó, Juan Carlos
  • Álvarez Escudero, María Rocío
  • Montes, Nuria
  • Gago-Veiga, Ana Beatriz|||0000-0002-0038-3406
Background and purpose: According to the latest European guidelines, discontinuation of monoclonal antibodies against calcitonin gene-related peptide (anti-CGRP MAb) may be considered after 12-18 months of treatment. However, some patients may worsen after discontinuation. In this study, we assessed the response following treatment resumption. Methods: This was a prospective study conducted in 14 Headache Units in Spain. We included patients with response to anti-CGRP MAb with clinical worsening after withdrawal and resumption of treatment. Numbers of monthly migraine days (MMD) and monthly headache days (MHD) were obtained at four time points: before starting anti-CGRP MAb (T-baseline); last month of first treatment period (T-suspension); month of restart due to worsening (T-worsening); and 3 months after resumption (T-reintroduction). The response rate to resumption was calculated. Possible differences among periods were analysed according to MMD and MHD. Results: A total of 360 patients, 82% women, with a median (interquartile range [IQR]) age at migraine onset of 18 (12) years. The median (IQR) MHD at T-baseline was 20 (13) and MMD was 5 (6); at T-suspension, the median (IQR) MHD was 5 (6) and MMD was 4 (5); at T-worsening, the median (IQR) MHD was 16 (13) and MMD was 12 (6); and at T-reintroduction, the median (IQR) MHD was 8 (8) and MHD was 5 (5). In the second period of treatment, a 50% response rate was achieved by 57.4% of patients in MHD and 65.8% in MMD. Multivariate models showed significant differences in MHD between the third month after reintroduction and last month before suspension of first treatment period (p < 0.001). Conclusion: The results suggest that anti-CGRP MAb therapy is effective after reintroduction. However, 3 months after resumption, one third of the sample reached the same improvement as after the first treatment period.